vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and SPS COMMERCE INC (SPSC). Click either name above to swap in a different company.
SPS COMMERCE INC is the larger business by last-quarter revenue ($192.7M vs $177.4M, roughly 1.1× Pacira BioSciences, Inc.). SPS COMMERCE INC runs the higher net margin — 13.4% vs 1.6%, a 11.8% gap on every dollar of revenue. On growth, SPS COMMERCE INC posted the faster year-over-year revenue change (12.7% vs 5.0%). Over the past eight quarters, SPS COMMERCE INC's revenue compounded faster (13.5% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
SPS Commerce, Inc. is a technology and application software company based in the United States that provides cloud-based supply chain management software. The company's headquarters are located in Minneapolis, Minnesota, but it also has a US office in New Jersey, and international locations in Amsterdam, Beijing, Breukelen, Hong Kong, Kyiv, Melbourne, Montpellier, Sydney, and Toronto.
PCRX vs SPSC — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $192.7M |
| Net Profit | $2.9M | $25.8M |
| Gross Margin | — | 70.4% |
| Operating Margin | 3.9% | 18.0% |
| Net Margin | 1.6% | 13.4% |
| Revenue YoY | 5.0% | 12.7% |
| Net Profit YoY | — | 47.2% |
| EPS (diluted) | $0.07 | $0.69 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $192.7M | ||
| Q3 25 | $179.5M | $189.9M | ||
| Q2 25 | $181.1M | $187.4M | ||
| Q1 25 | $168.9M | $181.5M | ||
| Q4 24 | $187.3M | $170.9M | ||
| Q3 24 | $168.6M | $163.7M | ||
| Q2 24 | $178.0M | $153.6M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $25.8M | ||
| Q3 25 | $5.4M | $25.6M | ||
| Q2 25 | $-4.8M | $19.7M | ||
| Q1 25 | $4.8M | $22.2M | ||
| Q4 24 | — | $17.6M | ||
| Q3 24 | $-143.5M | $23.5M | ||
| Q2 24 | $18.9M | $18.0M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 70.4% | ||
| Q3 25 | 80.9% | 69.5% | ||
| Q2 25 | 77.4% | 68.1% | ||
| Q1 25 | 79.7% | 68.7% | ||
| Q4 24 | 78.7% | 67.5% | ||
| Q3 24 | 76.9% | 68.5% | ||
| Q2 24 | 75.1% | 66.1% |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | 18.0% | ||
| Q3 25 | 3.5% | 16.4% | ||
| Q2 25 | 4.7% | 14.1% | ||
| Q1 25 | 1.2% | 14.3% | ||
| Q4 24 | 13.2% | 14.5% | ||
| Q3 24 | -82.8% | 15.6% | ||
| Q2 24 | 15.9% | 15.1% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | 13.4% | ||
| Q3 25 | 3.0% | 13.5% | ||
| Q2 25 | -2.7% | 10.5% | ||
| Q1 25 | 2.8% | 12.2% | ||
| Q4 24 | — | 10.3% | ||
| Q3 24 | -85.1% | 14.3% | ||
| Q2 24 | 10.6% | 11.7% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $0.69 | ||
| Q3 25 | $0.12 | $0.67 | ||
| Q2 25 | $-0.11 | $0.52 | ||
| Q1 25 | $0.10 | $0.58 | ||
| Q4 24 | $0.38 | $0.46 | ||
| Q3 24 | $-3.11 | $0.62 | ||
| Q2 24 | $0.39 | $0.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $151.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $653.9M | $973.9M |
| Total Assets | $1.2B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $151.4M | ||
| Q3 25 | $246.3M | $133.7M | ||
| Q2 25 | $445.9M | $107.6M | ||
| Q1 25 | $493.6M | $94.9M | ||
| Q4 24 | $484.6M | $241.0M | ||
| Q3 24 | $453.8M | $205.8M | ||
| Q2 24 | $404.2M | $271.8M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $973.9M | ||
| Q3 25 | $727.2M | $958.9M | ||
| Q2 25 | $757.8M | $949.8M | ||
| Q1 25 | $798.5M | $920.9M | ||
| Q4 24 | $778.3M | $854.7M | ||
| Q3 24 | $749.6M | $829.4M | ||
| Q2 24 | $879.3M | $703.4M |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $1.2B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.5B | $1.1B | ||
| Q1 25 | $1.6B | $1.1B | ||
| Q4 24 | $1.6B | $1.0B | ||
| Q3 24 | $1.5B | $1.0B | ||
| Q2 24 | $1.6B | $854.5M |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $45.9M |
| Free Cash FlowOCF − Capex | — | $38.2M |
| FCF MarginFCF / Revenue | — | 19.8% |
| Capex IntensityCapex / Revenue | — | 4.0% |
| Cash ConversionOCF / Net Profit | — | 1.78× |
| TTM Free Cash FlowTrailing 4 quarters | — | $152.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $45.9M | ||
| Q3 25 | $60.8M | $60.6M | ||
| Q2 25 | $12.0M | $32.3M | ||
| Q1 25 | $35.5M | $40.0M | ||
| Q4 24 | $33.1M | $40.6M | ||
| Q3 24 | $53.9M | $53.3M | ||
| Q2 24 | $53.2M | $29.4M |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $38.2M | ||
| Q3 25 | $57.0M | $54.6M | ||
| Q2 25 | $9.3M | $25.7M | ||
| Q1 25 | $26.9M | $33.8M | ||
| Q4 24 | $31.0M | $34.3M | ||
| Q3 24 | $49.8M | $48.1M | ||
| Q2 24 | $51.6M | $24.4M |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | 19.8% | ||
| Q3 25 | 31.7% | 28.7% | ||
| Q2 25 | 5.1% | 13.7% | ||
| Q1 25 | 15.9% | 18.6% | ||
| Q4 24 | 16.6% | 20.1% | ||
| Q3 24 | 29.6% | 29.4% | ||
| Q2 24 | 29.0% | 15.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 4.0% | ||
| Q3 25 | 2.2% | 3.2% | ||
| Q2 25 | 1.5% | 3.6% | ||
| Q1 25 | 5.1% | 3.4% | ||
| Q4 24 | 1.1% | 3.6% | ||
| Q3 24 | 2.4% | 3.2% | ||
| Q2 24 | 0.9% | 3.3% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.78× | ||
| Q3 25 | 11.20× | 2.37× | ||
| Q2 25 | — | 1.64× | ||
| Q1 25 | 7.37× | 1.80× | ||
| Q4 24 | — | 2.31× | ||
| Q3 24 | — | 2.27× | ||
| Q2 24 | 2.82× | 1.63× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
SPSC
| Recurring Revenues | $184.5M | 96% |
| One Time Revenues | $8.1M | 4% |
| Set Up Fees | $4.1M | 2% |
